5:09 PM
 | 
Jan 23, 2012
 |  BC Extra  |  Clinical News

Advanced Cell reports first data from stem cell trials

Advanced Cell Technology Inc. (OTCBB:ACTC) said the sub-retinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in two patients with ophthalmic disease showed no adverse safety issues and produced improvements in vision at four months following...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >